biopTumor-Informed Liquid Biopsies to Transform Oncology Drug Development

Abstract

Get full access to this article

View all access options for this article.

References

Boyle

et al. A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimal residual disease at part per million resolution; Poster presented at: 2022 Annual Meeting of the American Association for Cancer Research; April 8, 2022; New Orleans, LA.

Wouters

et al. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009–2018. JAMA , 2020; 323(9): 844–853.

Rouprêt

, Gschwend

. Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): Update from IMvigor010. Proceedings of the 2022 European Association of Urology Annual Congress. July 4, 2022; Amsterdam.

Bidard

et al. Fulvestrant-palbociclib vs. continuing AI-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2–metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial. Proceedings of the 2021 San Antonio Breast Cancer Symposium. December 9, 2021. San Antonio, TX.